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Abstract
Background:  Severe  alcoholic  hepatitis  (SAH)  presents  high  early  mortality-rate  (90  days)  and
is related  to  several  complications.  The  aim  of  this  study  was  to  evaluate  the  impact  on  early
mortality-rate  of  developed  complications  in  patients  with  SAH,  and  to  evaluate  the  accuracy
of different  prognostic  scoring  systems  to  predict  early  mortality.
Subjects  and  methods:  Cohort  study.  Were  included  110  patients  with  SAH.  We  collected  data
about development  of  complications:  acute  renal  failure  (ARF),  hepatic  encephalopathy  (HE),
variceal bleeding  (VB),  infections;  alcohol  intake  (g/day)  and  presence  of  cirrhosis  by  ultra-
sonography  (USG).  Child-Pugh,  Maddrey’s  modiﬁed  discriminant  function  (DF),  Model  for  End
stage Liver  Disease  (MELD);  Age,  Bilirubin,  INR,  and  Creatinine  score  (ABIC);  Lille  score,  and
Glasgow Alcoholic  Hepatitis  Score  (GAHS)  were  calculated.  Primary  endpoint  was  90-day  mor-
tality. To  evaluate  survival  according  to  the  development  of  complications  we  performed  a  Cox
regression  model.  Accuracy  of  different  prognostic  scoring  systems  was  evaluated  trough  ROC
curves.
Results: 90-day  mortality-rate  was  71  patients  (64.5%).  79  patients  (71.8%)  had  evidence  of
cirrhosis in  the  USG,  59  (53.6%)  developed  HE,  54  (49.1%)  ARF,  41  (37.3%)  VB,  and  41  (37.3%)
infection. In  the  Cox-regression  model  signiﬁcant  association  was  found  between  greater  risk  of
mortality  and  the  development  of  HE  (HR  8.0;  IC  al  95%  3.0  a  21.4;  P  =  0.0001)  and  presence  of
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cirrhosis  in  the  USG  (HR  3.0;  95%  CI  1.0  to  8.7;  P  =  0.045).  Regard  to  prognostic  scoring  systems
we found  that  Lille  score  ≥  0.45  was  the  best  predictor  of  early  mortality  in  patients  with  SAH
(AUROC =  0.83;  95%  CI  0.75  to  0.91,  P  <  0.0001).
Conclusions:  The  development  of  HE  is  the  main  factor  associated  to  early  mortality.  Coexis-
tence of  cirrhosis  is  a  factor  that  worsen  the  prognosis.  Lille  score  is  the  most  accurate  for
predict early  mortality.
© 2014  Sociedad  Médica  del  Hospital  General  de  México.  Published  by  Masson  Doyma  México
S.A. All  rights  reserved.
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Principales  factores  clínicos  que  inﬂuyen  en  la  mortalidad  temprana  en  una  cohorte
de  pacientes  con  hepatitis  alcohólica  severa,  y  evaluación  a  través  de  curvas  COR  de
diferentes  sistemas  pronósticos
Resumen
Antecedentes:  La  hepatitis  alcohólica  severa  (HAS)  presenta  elevada  mortalidad  a  corto  plazo
(90 días)  y  se  asocia  a  diversas  complicaciones.  El  objetivo  de  este  estudio  fue  valorar  el  impacto
que tienen  las  complicaciones  desarrolladas  en  pacientes  con  HAS  sobre  la  mortalidad  temprana
y evaluar  la  exactitud  de  diferentes  índices  para  predecir  mortalidad  a  corto  plazo.
Materiales  y  métodos:  Estudio  de  cohorte.  Se  incluyeron  110  pacientes  con  diagnóstico  de  HAS.
Se registraron  desarrollo  de  complicaciones:  Insuﬁciencia  renal  aguda  (IRA),  encefalopatía  hep-
ática (EH),  hemorragia  variceal  (HV),  infecciones,  consumo  de  alcohol  (g/día)  y  presencia  de
cirrosis por  ultrasonido  (USG).  Se  calcularon  Child-Pugh;  función  discriminante  modiﬁcada  de
Maddrey; Model  for  End  stage  Liver  Disease  (MELD);  Age,  Bilirubin,  INR,  and  Creatinine  score
(ABIC); puntuación  de  Lille,  escala  de  hepatitis  alcohólica  de  Glasgow  (GAHS).  El  desenlace
primario fue  mortalidad  a  90  días.  Para  evaluar  supervivencia  en  relación  al  desarrollo  de  com-
plicaciones  se  realizó  regresión  de  Cox.  La  exactitud  de  los  diferentes  índices  pronósticos  se
evaluó mediante  curvas  COR.
Resultados:  La  mortalidad  a  90  días  fue  de  71  pacientes  (64.5%).  79  pacientes  (71.8%)  tenían
evidencia de  cirrosis  por  USG,  59  (53.6%)  desarrollaron  EH,  54  (49.1%)  IRA,  41  (37.3%)  HV,  y
41 (37.3%)  infección.  En  el  análisis  de  regresión  de  Cox  se  encontró  asociación  entre  riesgo  de
mortalidad  y  desarrollo  de  EH  (HR  8.0;  IC  al  95%  3.0  a  21.4;  P  =  0.0001)  y  presencia  de  cirrosis
en USG  (HR  3.0;  IC  al  95%  1.0  a  8.7;  P  =  0.045).  Respecto  a  los  índices  pronósticos  el  puntaje  de
Lille ≥  0.45  fue  el  mejor  predictor  de  mortalidad  temprana  en  pacientes  con  HAS  (ABC  =  0.83;
IC al  95%  0.75  a  0.91,  P  <  0.0001).
Conclusiones:  El  desarrollo  de  EH  es  el  principal  factor  asociado  a  mortalidad  temprana.  La
coexistencia  de  cirrosis  es  un  factor  que  empeora  el  pronóstico.  El  puntaje  de  Lille  es  el  más
exacto para  predecir  mortalidad  temprana.
© 2014  Sociedad  Médica  del  Hospital  General  de  México.  Publicado  por  Masson  Doyma  México
S.A. Todos  los  derechos  reservados.
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Severe  alcoholic  hepatitis  (SAH)  is  a  pathological  condition
associated  with  a  high  risk  short-term  mortality  (90  days),
without  treatment,  50%  of  patients  die  within  the  ﬁrst  two
months.1--4 Treatment  with  corticosteroids  or  pentoxifylline
has  demonstrated  improvement  on  survival,  nevertheless,
immediate  mortality  remains  ranging  from  15%  to  50%
of  cases  according  to  severity.5 Several  factors,  such  as,
excessive  alcohol  intake  and  cirrhosis,  age,  liver  failure,
gastrointestinal  bleeding,  concomitant  viral  B  or  C  infection
and  persistent  alcohol  intake,  have  been  identiﬁed  as  inde-
pendent  poor  prognostic  markers  in  patients  with  chronic
liver  disease.6 In  patients  with  SAH,  the  development  of
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pomplications,  such  as,  hepatic  encephalopathy  (HE)  or  hep-
torenal  syndrome  has  a  negative  impact  on  survival.7
Several  scoring  systems  are  available  to  establish  a  prog-
osis  in  patients  with  SAH.  The  clinical  utility  of  the  different
coring  systems  has  been  compared  by  several  studies  with
onﬂicting  results.8 Is  true  that  Maddrey’s  modiﬁed  discrim-
nant  function  (DF)  is  a  useful  tool  to  determine  need  for
herapy  if  it  is  ≥  32.9 However,  to  assess  the  prognosis  of
atients  with  SAH,  several  studies  have  demonstrated  that
he  Model  for  End-stage  Liver  Disease  (MELD)  score,  the
lasgow  Alcoholic  Hepatitis  Score  (GAHS),  and  the  Hepatic
enous  Pressure  Gradient  (HVPG)  are  better  predictors  of
urvival  than  DF.10--17 The  Lille  score  has  shown  to  identify
atients  who  do  not  respond  to  corticosteroids  therapy,  with
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n  increased  risk  of  death  in  the  next  6  months.18 The  Age,
ilirubin,  INR,  and  Creatinine  (ABIC)  score  identify  patients
ith  low,  intermediate  and  high  risk  of  death  at  90  days  and
t  1  year.19
The  aim  of  this  study  was  to  evaluate  the  impact  on
arly  mortality-rate  (90  days)  of  developed  complications  in
atients  with  SAH,  and  to  evaluate  the  accuracy  of  different
rognostic  scoring  systems  to  predict  early  mortality.
ubjects and methods
tudy  design
bservational,  prospective,  cohort  study.  We  evaluated  121
atients.  Were  included  110  patients  with  SAH  diagnosis
ho  were  attended  at  Gastroenterology  Department  from
‘Hospital  General  de  México’’  from  April  2010  to  May
012.  We  excluded  patients  with  concomitant  comorbidi-
ies:  chronic  hepatitis  C  (4),  chronic  hepatitis  B  (1),  diabetes
3),  concomitant  use  of  herbal  (3).
rocedure
e  collected  data  about  development  of  complications:
cute  renal  failure  (ARF),  HE,  variceal  bleeding  (VB),  infec-
ions;  alcohol  intake  expressed  as  g/day  and  presence
f  cirrhosis  in  the  ultrasonography  (USG).  Child-Pugh,  DF,
ELD,  ABIC,  Lille  score,  and  GAHS  were  calculated.  Primary
ndpoint  was  mortality  at  90  days.
eﬁnitions
evere  alcoholic  hepatitis  (SAH)
as  deﬁned  according  to  clinical  and  biochemical  parame-
ers  as  follows:  History  of  chronic  and  heavy  alcohol  intake
reater  than  80  g/day  in  the  last  5  years,  with  rapid  onset
f  jaundice  in  the  absence  of  biliary  tract  obstruction  by
ltrasound,  with  painful  hepatomegaly  and  ascites,  raised
ransaminases  more  than  two  times  above  the  normal  value,
spartate  aminotransferase  (AST)/alanine  aminotransferase
ALT)  ratio  greater  than  2  times  normal  value,  leukocyto-
is  with  predominance  of  neutrophils,  total  bilirubin  greater
han  5  mg/dL,  DF  greater  than  32,  calculated  with  the  for-
ula  [4.6  x(patient  prothrombin  time  (PT)  --control  PT,  in
econds)+  Total  bilirubin  in  mg/dL].7,20
cute  renal  failure  (ARF)
his  condition  was  deﬁned,  according  to  the  criteria  from
he  Acute  Kidney  Injury  Network,  as  the  abrupt  reduction
48  hours)  of  renal  function,  characterized  by  an  increase
f  0.3  mg/dL  in  the  serum  creatinine  compared  with  the
aseline  value.  Patients  who  had  a  baseline  value  of  serum
reatinine  greater  than  1.5  mg/dL  at  the  time  of  admission
ere  considered  ARF  cases.21,22epatic  encephalopathy  (HE)
his  condition  was  deﬁned  clinically  by  neuropsychiatric
lterations  and  neuromuscular  signs  according  to  the  West-
aven  criteria.23
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ariceal  bleeding  (VB)
his  condition  was  deﬁned  by  the  presence  of  melena
r  hematemesis  associated  with  gastroesophageal  varices
etermined  by  endoscopy.24
pontaneous  bacterial  peritonitis  (SBP)
as  deﬁned  according  to  the  guidelines  of  the  American
ssociation  for  Study  of  Liver  Diseases,  as  an  ascites  neu-
rophil  count  greater  than  250/mm3.25
ther  infections
neumonia  was  diagnosed  in  patients  who  developed  cough
ith  expectoration  and  consolidation  in  the  chest  X-ray.  Uri-
ary  tract  infection  was  diagnosed  in  patients  having  urinary
ymptoms  associated  with  abnormal  urinary  examination
nd  urinary  cultures,  including  a  bacterial  count  greater
han  100,000  CFU.  Patients  with  diarrhea  were  evaluated
y  microscopic  fresh  stool  examination  and  stool  cul-
ures.  When  patients  developed  odynophagia  or  dysphagia,
sophageal  candidiasis  was  considered.  The  diagnosis  was
onﬁrmed  through  oral  cavity  examination  and  endoscopy
ith  the  presence  of  compatible  lesions;  brushing  for  myco-
ogical  examination  was  performed  in  all  cases.
oexistence  of  cirrhosis  by  USG
hese  data  was  collected  from  the  report  of  the  radiolo-
ist  according  to  ultrasonographic  ﬁndings  such  as,  increased
oarsened  and  heterogeneous  echo  texture  of  the  liver,  sur-
ace  nodularity,  segmental  hypertrophy/atrophy  including
audate  width/right  lobe  width  >  0.65,  signs  of  portal  hyper-
ension,  including  enlarged  portal  vein  >  13  mm,  enlarged
uperior  mesenteric  vein  (SMV)  and  splenic  vein  >  10  mm,
oss  of  respiratory  variation  in  SMV  and  splenic  vein  diam-
ter,  reversal  or  to-and-fro  portal  vein  ﬂow,  portal  vein
hrombosis  and/or  cavernous  transformation,  portalization
f  hepatic  vein  waveform,  recanalization  and  hepatofugal
araumbilical  venous  ﬂow,  portosystemic  collaterals.26
tatistical  analysis
he  distribution  of  numerical  variables  were  analyzed
ith  Kolmogorov-Smirnov  test,  asymmetry  and  kurtosis,  in
ase  of  non-normal  distribution  were  expressed  as  median
nd  range,  and  in  case  of  normal  distribution  as  mean
nd  standard  deviation  (SD).  Qualitative  variables  were
xpressed  as  proportion  and  percentage.  To  evaluate  sur-
ival  according  to  the  development  of  complications  we
erformed  a  Cox  regression  model.  Accuracy  of  differ-
nt  prognostic  scoring  systems  was  evaluated  trough  ROC
urves.  A  P  value  ≤  0.05  was  considered  signiﬁcant.  SPSS
ersion  19.0  was  employed.
esults
03  patients  (93.6%)  were  male.  Media  of  age  was  43.3  ±  9.3
ear-old.  Media  of  alcohol  intake  was  342  ±  170  g/day.
bout  treatment,  70  patients  (63.6%)  received  prednisone
0  mg/day  and  40  (36.4%)  were  treated  with  pentoxifylline
00  mg  thrice  in  day.  Mortality  rate  at  90  days  was  71
atients  (64.5%).  All  patients  were  classiﬁed  as  Child-Pugh
.  79  patients  (71.8%)  had  evidence  of  cirrhosis  in  the  USG,
Clinical  factors  inﬂuencing  mortality  in  severe  alcoholic  hepatiti
Table  1  Cox  regression  model  evaluating  main  determi-
nant clinical  factors  associated  to  mortality  at  90  days  in
patients  with  severe  alcoholic  hepatitis.
Covariables  HR  95%  CI  P
Cirrhosis  3.0  1.0  a  8.7  0.045
Hepatic  encephalopathy  8.0  3.0  a  21.4  0.0001
Acute renal  failure  1.6  0.7  a  3.9  0.260
Variceal  bleeding  0.8  0.4  a  1.3  0.297
Infection  1.1  0.7  a  1.9  0.627
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P ≤ 0.05 was considered signiﬁcant.
59  (53.6%)  developed  HE,  54  (49.1%)  developed  ARF,  41
(37.3%)  developed  VB,  41  (37.3%)  developed  infection.  The
reported  infections  were:  18  patients  (16.4%)  developed
esophageal  candidiasis,  10  (9.1%)  urinary  tract  infection,  7
(6.4%)  SBP,  4  (3.6%)  pneumonia,  2  (1.8%)  diarrhea.
In  the  Cox-regression  model  signiﬁcant  association  was
found  between  greater  risk  of  mortality  and  the  develop-
ment  of  HE  (HR  8.0;  IC  al  95%  3.0  a  21.4;  P  =  0.0001)  and
presence  of  cirrhosis  in  the  USG  (HR  3.0;  95%  CI  1.0  to  8.7;
P  =  0.045).  See  table  1.
Regard  to  prognostic  scoring  systems  we  found  that  Lille
score  ≥  0.45  was  the  best  predictor  of  early  mortality
in  patients  with  SAH  (AUROC  =  0.83;  95%  CI  0.75  to  0.91,
P  <  0.0001).  See  table  2  and  ﬁgure  1.
Discussion
In  our  cohort  most  of  patients  were  male  (93.6%).  World-
wide,  men  are  more  likely  than  women  to  drink  excessively.
Excessive  drinking  is  associated  with  signiﬁcant  increases  in
short-term  risks  to  health  and  safety,  and  the  risk  increases
as  the  amount  of  drinking  increases.27--31 Patterns  of  alcohol
consumption  also  is  different  between  men  and  women,  for
example,  men  average  about  12.5  binge  drinking  episodes
per  person  per  year,  while  women  average  about  2.7  binge
drinking  episodes  per  year.28 Proportion  of  patients  who
meet  criteria  for  alcohol  dependence  is  greater  in  men  than
Table  2  Comparision  between  of  the  area  under  de  curve
of different  prognostic  scoring  systems  to  predict  mortality
at 90  days  in  patients  with  severe  alcoholic  hepatitis.
Prognostic  Scoring  System  AUROC  95%  CI  P
Child-Pugh  0.60  0.49--0.71  0.09
DF 0.67  0.57--0.78  0.003
MELD 0.70  0.59--0.80  0.001
GAHS 0.67  0.57--0.77  0.003
ABIC 0.65  0.54--0.76  0.01
Alcohol  intake  (g/day)  0.56  0.45--0.66  0.3
Lille model  0.83  0.75--0.91  <  0.0001
ABIC = Age-Bilirubin-INR-Creatinine score; AUROC = area under
de receiver operating charcteristic curve; CI = conﬁdence
interval; DF = Maddrey’s modiﬁed discriminant function;
GAHS = Glasgow Alcoholic Hepatitis Score; MELD = Model for
End-stage Liver Disease.
P ≤ 0.05 was considered signiﬁcant.
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n  women  (17%  vs.  8%,  respectively).32 Men  consistently  have
igher  rates  of  alcohol-related  deaths  and  hospitalizations
han  women.33,34
In  our  cohort,  the  media  of  age  was  43.3  ±  9.3  year-old.  In
exico,  cirrhosis  and  other  chronic  liver  diseases  represents
he  second  cause  of  death  in  economically  active  population
age  ranging  from15  to  64  year-old).35
About  treatment,  70  patients  (63.6%)  received  pred-
isone  40  mg/day  and  40  (36.4%)  were  treated  with
entoxifylline  400  mg  thrice  in  day.  Actually,  corticosteroids
re  recommended  as  the  ﬁrst  line  therapy  for  severe  alco-
olic  hepatitis,  pentoxifylline  usually  is  reserved  for  those
ases  with  any  contraindication  for  corticosteroids  use;
uch  as,  gastrointestinal  bleeding;  active  bacterial,  viral
r  fungal  infections;  or  acute  renal  failure.36 An  advan-
age  from  the  treatment  with  pentoxifylline,  is  that  has
emonstrated  protective  effect  against  development  of
epatorenal  syndrome.37--40 However,  there  is  no  evidence
bout  signiﬁcant  difference  in  survival-rate  at  30  days
etween  patients  treated  with  corticosteroids  and  those
reated  with  pentoxifylline.39,40
Mortality  rate  at  90  days  in  our  cohort  was  64.5%.  Alco-
olic  hepatitis  is  a  distinct  clinical  syndrome  among  people
ith  chronic  and  active  alcohol  abuse,  with  a  potential  for  30
 40%  mortality  at  1  month  among  those  with  severe  disease.
orticosteroids  or  pentoxifylline  are  the  current  pharmaco-
ogic  treatment  options,  but  they  provide  only  about  50%
urvival  beneﬁt.41
In  our  study,  main  clinical  risk  factor  associated  with
ortality  in  patients  with  SAH,  were  concomitant  cirrhosis
emonstrated  by  USG  and  the  development  of  HE.  How-
ver,  several  are  the  clinical  factors  associated  with  poor
rognosis  and  short-term  mortality  in  patients  with  SAH.
ltamirano  J,  et  al,42 found  that  alcohol  intake  ≥120  g/day
as  associated  with  greater  mortality-rate  in  a cohort  of
exican  patients.  However,  when  we  evaluated  the  alco-
ol  intake  isolated  as  a  prognostic  test,  we  identiﬁed  that
his  parameter  is  not  the  best  for  this  purpose.  Potts  JR,
t  al,43 in  a  large  cohort  of  English  patients,  found  that  the
verall  mortality  was  57.8%,  96.8%  of  deaths  being  liver-
elated  and  65.1%  occurring  after  the  index  hospitalization.
epatorenal  syndrome  was  the  only  baseline  factor  indepen-
ently  associated  with  short-term  mortality  (HR  3.78,  95%  CI
.98--7.19,  P  <  0.0001).  Zhao  JM,  et  al,44 evaluated  factors
elated  to  mortality  in  patients  with  severe  hepatitis  for  sev-
ral  causes,  they  found  that  mortality  was  higher  in  patients
ith  cirrhosis  compared  with  non-cirrhotic  patients  (40%  vs.
.3%,  P  =  0.002).  Also,  patients  without  HE  had  lower  mortal-
ty  than  with  HE  (3.33%  vs  46.51%).  The  mortality  of  patients
ith  HE  Stage  III  and  IV  was  72.73%.  Finally,  the  results
f  multivariate  conditional  logistic  regression  analysis  indi-
ated  that  HE,  serum  creatinine  levels  were  risk  factors  for
eath.  Recently,  Orntoft  NW,  et  al,45 found  that  most  deaths
ithin  the  ﬁrst  84  days  after  admission  in  patients  with
lcoholic  hepatitis  resulted  from  liver  failure  (40%),  infec-
ions  (20%),  or  hepatorenal  syndrome  (11%).  Beyond  84  days,
auses  of  deaths  differed  between  patients  with  and  without
irrhosis;  cirrhosis  was  present  in  51%  of  patients  diagnosed
ith  alcoholic  hepatitis;  most  patients  without  cirrhosis  died
f  causes  related  to  alcohol  abuse,  whereas  most  patients
ith  cirrhosis  (n  =  675)  died  of  liver  failure  (34%),  infections
16%),  or  VB  (11%).
164  F.  Higuera-de  la  Tijera  et  al.
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Figure  1  Area  under  de  receiver  operating  characteristic  (ROC)  curve  of  different  prognostic  scoring  systems  to  predict  mortality
at 90  days  in  patients  with  severe  alcoholic  hepatitis.
ABIC  =  Age-Bilirubin-International  normalized  ratio-Creatinine  score;  DF  =  Maddrey’s  modiﬁed  discriminant  function;  GAHS  =  Glasgow
Alcoholic Hepatitis  Score;  MELD  =  Model  for  End-stage  Liver  Disease.
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dIn  our  study,  infections  did  not  represent  a  major  cause
f  death  in  patients  with  SAH.  However,  other  authors
ave  reported  bacterial  infections  as  a  main  cause  of
eath.46--49 Immune  system  dysfunction  has  been  reported
n  patients  with  SAH.  Neutrophils  are  an  essential  compo-
ent  of  the  innate  immune  response  and  key  players  in
he  pathogenesis  of  alcoholic  hepatitis.  Jaeschke  H,  et  al,50
ound  decreased  neutrophil  phagocytic  capacity  correlating
ith  disease  severity.  Mookerjee  RP,  et  al,51 also  demon-
trated  neutrophil  dysfunction  in  patients  with  alcoholic
epatitis.52 Regard  to  infections  found  in  our  patients,  is
oteworthy  that  the  most  frequent  was  esophageal  candidi-
sis,  an  explanation  for  this  ﬁnding  could  be  the  potential
ide-effects  of  corticosteroids  that  are  numerous,  includ-
ng  anti-anabolism,  muscle  breakdown,  immunosuppression,
ncreased  susceptibility  to  infection,  and  increased  risk  of  GI
leeding.53
Several  studies  have  compared  the  accuracy  to  predict
ortality-rate  of  the  available  prognostic  systems,  never-
heless,  this  is  the  ﬁrst  study  that  compared  the  ﬁve  main
coring  systems  available  to  assess  the  prognosis  in  alcoholic
epatitis  (Lille  score,  ABIC,  MELD,  DF,  GAHS).  This  study
emonstrated  that  response  to  treatment,  evaluated  trough
he  Lille  score  was  the  best  predictor  of  early  mortality  in
atients  with  SAH.  According  to  Lille  score,  patients  with
AH  are  classiﬁed  as  non-responders  if  Lille  score  results
bove  0.45.  In  the  original  study,  Louvet  A,  et  al,54 found
hat  non-responders  have  a  marked  decrease  in  6-month
urvival  as  compared  with  responders  (25%  +  /-  3.8%  versus
e
f
i5%  +  /-  2.5%,  P  <  0.0001).  A  very  important  variable  in
he  Lille  score  is  the  level  of  serum  bilirubin  at  7  days
fter  start  treatment  with  corticosteroids.  The  decrease  in
he  bilirubin  level  is  a crucial  determinant  of  response  to
reatment.54 In  a  study  by  Bargalló-García  A,  et  al,55 MELD
core,  urea  and  bilirubin  values  one  week  after  admission
ere  independently  associated  with  both  in-hospital  sur-
ival  (OR  =  1.14,  1.012  and  1.1,  respectively),  and  survival
t  6  months  (OR  =  1,  15;  1.014  and  1.016,  respectively).
In  our  study  MELD  was  identiﬁed  as  the  second  best  pre-
ictor  of  early  mortality  in  our  cohort,  this  is  consistent  with
esults  from  the  study  by  Bargalló-García  A55,  who  identiﬁed
he  MELD  score  as  the  best  scoring  system,  and  similar  to
BIC  when  compared  with  Child-Pugh  and  GAHS.  Other  sco-
ing  systems,  as  DF,  GASH,  and  ABIC  obtained  similar  AUROC
alues  in  our  study.
Is  an  important  limitation  of  our  study,  that  our  patients
ack  of  biopsy,  that  is  the  gold  standard  to  conﬁrm  the
iagnosis  of  alcoholic  hepatitis.  Furthermore,  our  diagno-
is  of  concomitant  cirrhosis  was  based  on  ultrasonographic
hanges,  and  is  well  known  that  this  is  not  the  best
ethod  to  conﬁrm  the  presence  of  cirrhosis.  Also,  a  good
roportion  of  patients  in  this  cohort  received  treatment
ith  pentoxifylline,  and  it  is  well  kwon  that  this  drug  is
 nephro-protective  agent  against  hepatorenal  syndrome
evelopment  in  patients  with  SAH,  thus,  this  fact  could
xplain  that  in  this  cohort,  ARF  did  not  represent  a  risk  factor
or  death,  but  this  asseveration  was  not  formally  analyzed
n  our  study.
atiti
1
1
1
1
2
2
2
2
2
2
2
2
2
2
3
3
3
3
3
3Clinical  factors  inﬂuencing  mortality  in  severe  alcoholic  hep
Conclusions
The  development  of  HE  is  the  main  factor  associated  to  early
mortality.  Coexistence  of  cirrhosis  is  a  factor  that  worsen  the
prognosis  in  patients  with  SAH.  Lille  score  is  the  most  accu-
rate  for  predict  early  mortality,  then,  we  could  infer  that
response  to  treatment  is  a  crucial  determinant  of  survival.
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